TB-500 (Thymosin Beta-4)

What it is

TB-500 is sold as a synthetic version of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid protein. Tβ4 binds actin, a structural protein inside cells, and helps regulate the cell movement involved in wound repair. (PubChem: Thymosin beta-4; Malinda et al., 1999)

Here is the identity problem: no regulatory or pharmacopeial standard defines what "TB-500" is. (The July 2026 verification pass found no USP monograph or other official identity standard; certificates of analysis and unofficial write-ups are not pharmacopeial standards.) The name may refer to full-length Tβ4 or only its roughly 7-amino-acid active fragment. Nearly all primary research is on full-length Tβ4. A study can therefore be real and still describe a different molecule from the one carrying the TB-500 label.

What humans actually show

• Animal studies: Many, and mostly pointed in the same direction: faster wound closure, better vascularization, and cardiac-, tendon-, or muscle-repair effects in rodents. But small-animal work is not a human recovery trial, the papers cluster in a few labs, and they mix full Tβ4 with the fragment. The foundational rat study reported reepithelialization increases of 42% over saline controls at 4 days and as much as 61% at 7 days. (Malinda et al., 1999)
• Even the animal story has seams: A famous 2004 Nature paper said Tβ4 helped mouse hearts regenerate. A later study found it does not reprogram epicardial cells into heart-muscle cells. The marquee claim did not hold in the same form. (Bock-Marquette 2004 vs. rebuttal, PMC3664360)
• Human studies: Two, both in indications unrelated to sports injury:
• Neurotrophic keratopathy (an eye disease), Phase 3: topical Tβ4 eye drop. N=18 (terminated early). Complete healing in 60% (active) vs. 12.5% (placebo) — but p=0.0656, not statistically significant. (PMC9820614)
• Venous stasis leg ulcers, Phase 2: topical Tβ4 gel, N=72, whose primary endpoint was safety/tolerability, not a powered efficacy win. (NCT00832091)
• What has NOT been studied: A 2026 scoping review screened 1,772 records and still found the strongest layer was preclinical. No human randomized trial supports TB-500 for tendon, muscle, or any athletic injury. That is the gap behind the Wolverine claim. (MDPI scoping review, 2026)

FDA and U.S. status

• Current status (July 25, 2026): Removed from Category 2 in the April 2026 action (effective ~April 22). PCAC issued narrowly favorable 8–6–1 advisory recommendations for both forms, but final FDA action has not been taken.
• PCAC recommendation: On July 23, 2026, PCAC voted 8 yes, 6 no, 1 abstain on TB-500 free base and 8 yes, 6 no, 1 abstain on TB-500 acetate, recommending inclusion for both forms. The exact question was whether each form should be placed on the 503A Bulks List. These recommendations are advisory: they do not approve TB-500, authorize a specific product, or themselves complete FDA's process. (FDA voting questions; FDA-linked Day 1 broadcast)
• Next regulatory event: FDA's written meeting record and final determination. (FDA meeting page)
• WADA / sport: Prohibited at all times (both in and out of competition). Exact classification (verified against the WADA 2026 Prohibited List): it appears under Section S2.3, "Growth Factors and Growth Factor Modulators," listed verbatim as "Thymosin-β4 and its derivatives, e.g. TB-500." S2 substances are Non-Specified and banned in and out of competition. The US military (DoD) adopts the WADA prohibited-substance framework. (WADA 2026 Prohibited List (PDF); BSCG)

Risks and warning limits

• Known side effects: The two small human trials reported no major safety signal over no more than 84 days. Thin, short-term data are not an established safety profile.
• Theoretical risk — angiogenesis: Tβ4 is explicitly pro-angiogenic (it promotes new blood-vessel growth). That mechanism is the basis for a theoretical concern that it could support tumor blood supply. No human oncology data confirms or refutes this — treat it as an open mechanistic question, not a demonstrated risk.
• The concrete near-term risk: unstandardized identity and purity (see What it is). You may not be getting the molecule the studies describe.

What people are hearing

• What people report: Injury recovery, often paired with BPC-157 as the "healing stack." That is an online pattern, not a trial result.
• Common misconceptions: "The Wolverine peptide heals any injury" (the injury evidence is preclinical); "clinically proven for tendon or muscle recovery" (the human trials were an eye disease and a leg ulcer); "safe and legal" (human safety data are thin, WADA prohibits it at all times, and FDA has not completed its compounding decision).
• Product reality: Research-grade and compounded material circulates under a name with no official identity standard.

What would change this answer

• FDA's written meeting record and final determination after the narrowly favorable 8–6–1 advisory recommendations.
• Independent human data for any musculoskeletal indication (none exists today).
• Whether TB-500 enters FDA enforcement independent of the GLP-1 crackdown.

Sources and records

• Malinda et al., 1999 — Tβ4 accelerates rat wound healing
• Neurotrophic keratopathy Phase 3 (N=18), IJMS 2023
• ClinicalTrials.gov NCT00832091 — venous ulcer Phase 2 (N=72)
• MDPI scoping review, 2026 — the evidence is preclinical
• FDA — exact PCAC voting questions (PDF)
• FDA-linked Day 1 archived broadcast — TB-500 votes
• Bock-Marquette 2004 (Nature) and the replication failure (PMC3664360)

We do not link to vendors, telehealth prescribers, or supplement sellers.